Table 3 Outcomes and adverse events of patients with high-dose daptomycin therapy
Characteristic | Total (n = 67) | Daptomycin dose (mg/kg) | ||
|---|---|---|---|---|
≤ 8 (n = 41) | > 8 (n = 26) | P value | ||
14-day mortality | 11 (16.4%) | 6 (14.6%) | 5 (19.2%) | 0.74 |
28-day mortality | 24 (35.8%) | 13 (31.7%) | 11 (42.3%) | 0.44 |
In-hospital mortality | 33 (49.3%) | 20 (48.8%) | 13 (50.0%) | 0.92 |
ICU patients (n = 41) | 28 (68.3%) | 17/24 (70.8%) | 11/17 (64.7%) | 0.74 |
Infection-related death | 9 (13.4%) | 5 (12.2%) | 4 (15.4%) | 0.73 |
ICU patients (n = 41) | 7 (17.1%) | 4/24 (16.7%) | 3/17 (17.6%) | >0.99 |
Clinical success | 52 (77.6%) | 32 (78.0%) | 20 (76.9%) | 0.91 |
All bacteremia (n = 54) | 43 (79.6%) | 27/32 (84.4%) | 16/22 (72.7%) | 0.32 |
MRSA (n = 38) | 28 (73.7%) | 18/23 (78.3%) | 10/15 (66.7%) | 0.47 |
Vancomycin MIC ≥ 2 μg/mL (n = 24) | 19 (79.2%) | 13/14 (92.9%) | 6/10 (60%) | 0.12 |
VRE (n = 18) | 12 (66.7%) | 7/12 (58.3%) | 5/6 (83.3%) | 0.60 |
Endocarditis (n = 11) | 6 (54.5%) | 2/3 (66.7%) | 4/8 (50.0%) | >0.99 |
Catheter-related bacteremia (n = 16) | 15 (93.8%) | 10/11 (90.9%) | 5/5 (100%) | 0.59 |
cSSTI (n = 16) | 14 (87.5%) | 7/9 (77.8%) | 7/7 (100%) | 0.48 |
Bone & joint infection (n = 9) | 6 (66.7%) | 4/6 (66.7%) | 2/3 (66.7%) | >0.99 |
Microbiological success | 55 (82.1%) | 36 (87.8%) | 19 (73.1%) | 0.19 |
Adverse events | ||||
Cytopenia | 47 (70.2%) | 28 (68.3%) | 19 (73.1%) | 0.68 |
Renal dysfunction | 14 (20.9%) | 8 (19.5%) | 6 (23.1%) | 0.73 |
Elevated AST/ALT | 20/66 (30.3%) | 12/41 (29.3%) | 8/25 (32.0%) | 0.82 |
CPK elevations | ||||
Any | 16 (29.2%) | 7/37 (18.9%) | 9/24 (37.5%) | 0.11 |
By definition | 4/61 (6.6%) | 0/37 (0%) | 4/24 (16.7%) | 0.02 |